FCCC LOGO Faculty Publications
Nitzkorski JR , Farma JM , Watson JC , Siripurapu V , Zhu F , Matteotti RS , Sigurdson ER
Outcome and Natural History of Patients with Stage IV Colorectal Cancer Receiving Chemotherapy Without Primary Tumor Resection
Annals of Surgical Oncology. 2012 Feb;19(2) :379-383
PMID: WOS:000299483200007   
Back to previous list
There is a trend toward nonsurgical management of patients with nonobstructing metastatic (stage IV) colorectal cancer (CRC), although some will eventually undergo surgery. We examined patients with metastatic CRC who were managed with an intact primary tumor. An institutional review board (IRB)-approved database was retrospectively reviewed. All patients presenting with stage IV CRC from 2000 to 2008 were identified and analyzed. Among the 255 patients identified, 112 were taken directly to the operating room for either primary tumor resection or colostomy/bypass. Among the remaining 143 patients, 97 were managed without developing primary tumor-related symptoms, and 14 (9.8%) developed significant primary tumor-related symptoms necessitating operative or endoscopic management. Of the patients who developed symptoms, oxaliplatin and/or irinotecan was used among 71.4% of patients, and bevacizumab in 50%. Forty-two patients in the series underwent elective primary tumor resection after receiving chemotherapy. No independent predictors for development of primary tumor-related symptoms could be identified after controlling for age, gender, tumor location, number of metastatic sites, and type of chemotherapy. Median overall survival was 34 months for those who underwent elective primary tumor resection after chemotherapy, and 16 months for those who failed chemotherapy and developed symptoms. Among patients with metastatic CRC without an initial indication for surgery, incidence of obstruction or perforation after initiating chemotherapy was low (9.8%). No predictors of primary tumor-related complications could be identified. Survival was favorable among the highly selected cohort of patients who underwent elective primary tumor resection after chemotherapy.
Nitzkorski, James R. Farma, Jeffrey M. Watson, James C. Siripurapu, Veeraiah Zhu, Fang Matteotti, Ronald S. Sigurdson, Elin R. Fox Chase Cancer Center Supported by the John A. Ridge, MD, PhD, Surgical Oncology Fellowship at Fox Chase Cancer Center (J.R.N.). This funding source had no role in the design and conduct of the study nor the collection, management, analysis, and interpretation of the data, nor the preparation, review, and approval of the manuscript. 24 Springer New york 881ko